Apimeds Pharmaceuticals US (APUS) Research & Development (2025)

Apimeds Pharmaceuticals US (APUS) reported Research & Development of $361104.0 for Q4 2025, down 41.73% quarter-over-quarter from $619693.0 in Q3 2025.

Apimeds Pharmaceuticals US (APUS) Research & Development (2025) Analysis & Trends

Apimeds Pharmaceuticals US has reported Research & Development for 1 years, with the latest figure at $361104.0 in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) R&D (Qtr)
1 Teva Pharmaceutical Industries 39.72 Bn 35.98 Bn 1.97 Bn 222.00 Mn
2 Zoetis 34.61 Bn 32.67 Bn 1.62 Bn 180.00 Mn
3 United Therapeutics 24.07 Bn 21.91 Bn 648.10 Mn 138.20 Mn
4 Aurora Cannabis 16.98 Bn 16.91 Bn 33.43 Mn 934,363.43
5 Neurocrine Biosciences 16.64 Bn 15.32 Bn 800.70 Mn 296.20 Mn
6 Elanco Animal Health 12.19 Bn 11.76 Bn 785.00 Mn 97.00 Mn
7 Alkermes 7.37 Bn 6.86 Bn -116.06 Mn 103.35 Mn
8 Hims & Hers Health 6.62 Bn 5.87 Bn 396.79 Mn 46.94 Mn
9 Lantheus Holdings 6.47 Bn 5.97 Bn 230.92 Mn 39.38 Mn
10 Apimeds Pharmaceuticals US 13.93 Mn 10.29 Mn - 361,104.00

Historic Data

Download Data
DateValue
Dec 31, 2025 361,104.00
Sep 30, 2025 619,693.00
Jun 30, 2025 651,784.00